EMA Stands Firm On Estradiol Cream Safety Measure After Doubts Over Impartiality
A warning must be placed on product packaging
After a 14-year-old legal dispute, the European Medicines Agency has now repeated its safety review of high-strength estradiol creams for treating vaginal atrophy and says it stands by its original recommendation to place a limit on how long patients should use these products.
You may also be interested in...
The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.